Want to see IN:THEMISMED full AI Analyst Report?
THEMISMED Stock Chart & Stats
₹102.50
₹17.25(6.68%)
At close: 4:00 PM EST
₹102.50
₹17.25(6.68%)
Day’s Range― - ―
52-Week Range₹65.00 - ₹147.99
Previous CloseN/A
Volume256.77K
Average Volume (3M)18.54K
Market Cap
₹11.37B
Enterprise Value₹6.98K
Total Cash (Recent Filing)₹91.50M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)28.1
Beta1.29
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)4.34
Shares Outstanding92,100,120
10 Day Avg. Volume6,526
30 Day Avg. Volume18,537
Financial Highlights & Ratios
PEG Ratio-5.72
Price to Book (P/B)1.58
Price to Sales (P/S)1.84
P/FCF Ratio-37.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Latest-Year Revenue GrowthThe latest-year revenue rebound shows meaningful demand and sales expansion across the company’s pharmaceutical business. If maintained, stronger top-line scale can improve manufacturing absorption, support reinvestment in products and distribution, and provide a foundation for recovering profitability over the next several quarters.
Manageable LeverageModerate leverage gives Themis Medicare a relatively manageable balance-sheet burden compared with a highly indebted operator. This preserves financial flexibility to fund operations and pursue business needs, while reducing the degree to which interest obligations could restrict longer-term capital allocation.
Established Pharmaceutical Manufacturing ModelA focused pharmaceutical manufacturing and commercialization model provides an established route to revenue through finished medicines and healthcare products. Continued participation in domestic and potentially export channels can support recurring customer relationships and allow growth across selected therapeutic areas.
Bears Say
Severe Margin ErosionThe sharp decline in gross margin and move to negative EBIT indicate that recent revenue growth is not translating efficiently into operating profit. Unless margins recover, weaker earnings quality could constrain reinvestment, reduce resilience, and limit the durability of the company’s top-line expansion.
Negative Operating And Free Cash FlowThe reversal to negative operating and free cash flow weakens internal funding capacity and makes cash conversion less dependable. Sustained weakness would increase working-capital and funding pressure, potentially limiting the company’s ability to support growth or absorb operational volatility without using additional financing.
Collapsed Return On EquityThe collapse in return on equity shows that the company’s sizable equity base is currently generating very limited shareholder returns. This signals poor capital productivity and reinforces concerns that the recent revenue rebound has not yet produced an economically attractive or sustainably profitable operating outcome.
Themis Medicare Limited News
THEMISMED FAQ
What was Themis Medicare Limited’s price range in the past 12 months?
Themis Medicare Limited lowest stock price was ₹65.00 and its highest was ₹147.99 in the past 12 months.
What is Themis Medicare Limited’s market cap?
Themis Medicare Limited’s market cap is ₹11.37B.
When is Themis Medicare Limited’s upcoming earnings report date?
Themis Medicare Limited’s upcoming earnings report date is Nov 12, 2026 which is in 48 days.
How were Themis Medicare Limited’s earnings last quarter?
Themis Medicare Limited released its earnings results on Aug 13, 2026. The company reported ₹2.672 earnings per share for the quarter.
Is Themis Medicare Limited overvalued?
According to Wall Street analysts Themis Medicare Limited’s price is currently Overvalued.
Does Themis Medicare Limited pay dividends?
Themis Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.41%. See more information on Themis Medicare Limited dividends here
What is Themis Medicare Limited’s EPS estimate?
Themis Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Themis Medicare Limited have?
Themis Medicare Limited has 92,100,120 shares outstanding.
What happened to Themis Medicare Limited’s price movement after its last earnings report?
Themis Medicare Limited reported an EPS of ₹2.672 in its last earnings report. Following the earnings report the stock price went down -3.391%.
Which hedge fund is a major shareholder of Themis Medicare Limited?
Currently, no hedge funds are holding shares in IN:THEMISMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Themis Medicare Limited
Themis Medicare Limited, along with its affiliated entities, is a pharmaceutical company that produces and supplies medicinal goods for both the Indian and international markets. Its product portfolio encompasses active pharmaceutical ingredients (APIs) and various drug formulations, designed for application across diverse medical domains such as anti-infectious conditions, malaria, tuberculosis, cardiovascular issues, health and wellness, cancer, eye diseases, and pain relief. Founded in 1969, the company operated under the name Themis Chemicals until 2001, when it officially changed to Themis Medicare Limited. The company's primary operations are directed from its Mumbai, India headquarters.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Venus Remedies Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―